4 terminated, 2 completed, 2 withdrawn, 1 active not recruiting. 7 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 2, Terminated 2, Withdrawn 2, Active not recruiting 1 |
| Phase 2 | 3 | Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Aravive, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer Paclitaxel, Batiraxcept - Recurrent High Grade Uterine Cancer | Phase 1 | Withdrawn | Washington University School of Medicine | 2024-10-31 | 2024-10-02 | |
| Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma batiraxcept, Nab paclitaxel, Gemcitabine - Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Aravive, Inc. | 34 | 2021-07-28 | 2023-10-30 |
| Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy AVB-S6-500, Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 | Withdrawn | Washington University School of Medicine | 2021-06-30 | 2021-09-29 | |
| Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer Batiraxcept, Paclitaxel, Placebo - Platinum-resistant Ovarian Cancer | Phase 3 | Terminated | Aravive, Inc. | 366 | 2021-04-22 | 2023-10-30 |
| Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Batiraxcept, Cabozantinib (Cabo), Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Aravive, Inc. | 72 | 2021-02-26 | 2023-10-30 |
| Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma Avelumab, AVB-S6-500 - Urothelial Carcinoma | Phase 1 | Active not recruiting | University of Oklahoma | 19 | 2020-02-17 | 2026-03-13 |
| Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy AVB-S6-500 - IgA Nephropathy | Phase 2 | Terminated | Aravive, Inc. | 1 | 2019-11-27 | 2022-02-10 |
| Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer AVB-S6-500, Paclitaxel (Pac), Pegylated liposomal doxorubicin (PLD) - Ovarian Cancer | Phase 1 | Completed | Aravive, Inc. | 53 | 2018-12-06 | 2023-02-13 |
| A Phase 1 AVB-S6-500 Safety and Tolerability Study AVB-S6-500, Placebo - Healthy Volunteer | Phase 1 | Completed | Aravive, Inc. | 43 | 2018-01-31 | 2018-08-09 |
Kidney Diseases (2) · Ovarian Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Fallopian Tube Neoplasms (1) · Glomerulonephritis, IGA (1) · Kidney Neoplasms (1) · Neoplasm Metastasis (1) · Proteinuria (1) · Recurrence (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urinary Bladder Neoplasms (1)
Paclitaxel (4) · AVB-500 fusion protein (2) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Chromosomes, Artificial, P1 Bacteriophage (1) · Gemcitabine (1) · Nivolumab (1) · Taxes (1) · VMBP protocol (1) · avelumab (1) · cabozantinib (1) · liposomal doxorubicin (1)
United States (7) · Belgium (1) · Canada (1) · China (1) · Czechia (1) · France (1) · Georgia (1) · Italy (1) · Poland (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
Abhishek Tripathi, MD (1) · Amy Franke (1) · David G Mutch, M.D. (1) · Francoise Desir (1) · Katherine C Fuh, M.D., Ph.D. (1) · Thomas C Marbury, MD (1)